179 related articles for article (PubMed ID: 37349598)
1. MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs' patients.
Catalano G; Zaza A; Banella C; Pelosi E; Castelli G; de Marinis E; Smigliani A; Travaglini S; Ottone T; Divona M; Del Principe MI; Buccisano F; Maurillo L; Ammatuna E; Testa U; Nervi C; Venditti A; Voso MT; Noguera NI
Leukemia; 2023 Aug; 37(8):1600-1610. PubMed ID: 37349598
[TBL] [Abstract][Full Text] [Related]
2. Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment.
Banella C; Catalano G; Travaglini S; Pelosi E; Ottone T; Zaza A; Guerrera G; Angelini DF; Niscola P; Divona M; Battistini L; Screnci M; Ammatuna E; Testa U; Nervi C; Voso MT; Noguera NI
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626170
[TBL] [Abstract][Full Text] [Related]
3. Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.
Xiang Z; Luo H; Payton JE; Cain J; Ley TJ; Opferman JT; Tomasson MH
J Clin Invest; 2010 Jun; 120(6):2109-18. PubMed ID: 20484815
[TBL] [Abstract][Full Text] [Related]
4. Hexokinase 3 enhances myeloid cell survival via non-glycolytic functions.
Seiler K; Humbert M; Minder P; Mashimo I; Schläfli AM; Krauer D; Federzoni EA; Vu B; Moresco JJ; Yates JR; Sadowski MC; Radpour R; Kaufmann T; Sarry JE; Dengjel J; Tschan MP; Torbett BE
Cell Death Dis; 2022 May; 13(5):448. PubMed ID: 35538058
[TBL] [Abstract][Full Text] [Related]
5. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.
Powell JA; Lewis AC; Zhu W; Toubia J; Pitman MR; Wallington-Beddoe CT; Moretti PA; Iarossi D; Samaraweera SE; Cummings N; Ramshaw HS; Thomas D; Wei AH; Lopez AF; D'Andrea RJ; Lewis ID; Pitson SM
Blood; 2017 Feb; 129(6):771-782. PubMed ID: 27956387
[TBL] [Abstract][Full Text] [Related]
6. Long non‑coding RNA SNHG14 affects the proliferation and apoptosis of childhood acute myeloid leukaemia cells by modulating the miR‑193b‑3p/MCL1 axis.
Wang X; Li W; Chen Y; Zhou L
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33300066
[TBL] [Abstract][Full Text] [Related]
7. Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition.
Chen L; Chen W; Mysliwski M; Serio J; Ropa J; Abulwerdi FA; Chan RJ; Patel JP; Tallman MS; Paietta E; Melnick A; Levine RL; Abdel-Wahab O; Nikolovska-Coleska Z; Muntean AG
Leukemia; 2015 Jun; 29(6):1290-300. PubMed ID: 25650089
[TBL] [Abstract][Full Text] [Related]
8. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
[TBL] [Abstract][Full Text] [Related]
9. The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness.
Thomas GE; Egan G; García-Prat L; Botham A; Voisin V; Patel PS; Hoff FW; Chin J; Nachmias B; Kaufmann KB; Khan DH; Hurren R; Wang X; Gronda M; MacLean N; O'Brien C; Singh RP; Jones CL; Harding SM; Raught B; Arruda A; Minden MD; Bader GD; Hakem R; Kornblau S; Dick JE; Schimmer AD
Nat Cell Biol; 2022 Jun; 24(6):872-884. PubMed ID: 35668135
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the Diagnostic Potential of miR-29a-3p and miR-92a-3p as Circulatory Biomarkers in Acute Myeloid Leukemia.
Gado MM; Mousa NO; Badawy MA; El Taweel MA; Osman A
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3625-3633. PubMed ID: 31870103
[TBL] [Abstract][Full Text] [Related]
11. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
[TBL] [Abstract][Full Text] [Related]
12. Codelivery of BCL2 and MCL1 Inhibitors Enabled by Phenylboronic Acid-Functionalized Polypeptide Nanovehicles for Synergetic and Potent Therapy of Acute Myeloid Leukemia.
Xie J; Zhao X; Zhang P; Zhang Y; Cheng R; Zhong Z; Deng C
Adv Sci (Weinh); 2023 Mar; 10(8):e2204866. PubMed ID: 36683178
[TBL] [Abstract][Full Text] [Related]
13. NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.
Chiou JT; Huang NC; Huang CH; Wang LJ; Lee YC; Shi YJ; Chang LS
J Cell Physiol; 2021 Nov; 236(11):7356-7375. PubMed ID: 33982799
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical Drug Metformin and MCL1 Inhibitor S63845 Exhibit Anticancer Activity in Myeloid Leukemia Cells via Redox Remodeling.
Valiulienė G; Vitkevičienė A; Skliutė G; Borutinskaitė V; Navakauskienė R
Molecules; 2021 Apr; 26(8):. PubMed ID: 33921161
[TBL] [Abstract][Full Text] [Related]
15. VCP cooperates with UBXD1 to degrade mitochondrial outer membrane protein MCL1 in model of Huntington's disease.
Guo X; Qi X
Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):552-559. PubMed ID: 27913212
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of LncRNA-UCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA-125a/hexokinase 2 pathway.
Zhang Y; Liu Y; Xu X
J Cell Biochem; 2018 Jul; 119(7):6296-6308. PubMed ID: 29663500
[TBL] [Abstract][Full Text] [Related]
17. The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance.
Ariës IM; Hansen BR; Koch T; van den Dungen R; Evans WE; Pieters R; den Boer ML
Haematologica; 2013 Dec; 98(12):1905-11. PubMed ID: 24142999
[TBL] [Abstract][Full Text] [Related]
18. FBP1-Altered Carbohydrate Metabolism Reduces Leukemic Viability through Activating P53 and Modulating the Mitochondrial Quality Control System In Vitro.
Xu Y; Tran L; Tang J; Nguyen V; Sewell E; Xiao J; Hino C; Wasnik S; Francis-Boyle OL; Zhang KK; Xie L; Zhong JF; Baylink DJ; Chen CS; Reeves ME; Cao H
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232688
[TBL] [Abstract][Full Text] [Related]
19. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow infiltrated natural killer cells predicted the anti-leukemia activity of MCL1 or BCL2 inhibitors in acute myeloid leukemia.
Dai YJ; He SY; Hu F; Li XP; Zhang JM; Chen SL; Zhang WN; Sun HM; Wang DW
Mol Cancer; 2021 Jan; 20(1):8. PubMed ID: 33402171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
